BECN1 and metabolic dysfunction-associated steatotic liver disease: Interestingly, Ezquerro et al. did not observe any changes in BECN1 transcript levels in the liver tissue of MASLD patients, regardless of their glycemic status (distinction of BECN1 levels between simple steatosis and MASH within the MASLD group was not performed) [79].